Paul Tudor Jones's LLY Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 46,758 shares of Eli Lilly and Company (LLY) worth $50.25 M, representing 0.09% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in LLY, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2014, adding 355,600 shares. Largest reduction occurred in Q3 2014, reducing 301,300 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Eli Lilly and Company (LLY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Eli Lilly and Company (LLY) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +46,758 | New Buy | 46,758 | $1074.68 |
| Q2 2025 | -54,006 | Sold Out | 0 | $0.00 |
| Q1 2025 | +51,006 | Add 1700.20% | 54,006 | $825.91 |
| Q4 2024 | +3,000 | New Buy | 3,000 | $772.00 |
| Q3 2024 | -1,510 | Sold Out | 0 | $0.00 |
| Q2 2024 | +1,510 | New Buy | 1,510 | $905.38 |
| Q1 2024 | -23,739 | Sold Out | 0 | $0.00 |
| Q4 2023 | +12,993 | Add 120.91% | 23,739 | $582.92 |
| Q3 2023 | +10,746 | New Buy | 10,746 | $537.13 |
| Q2 2023 | -15,198 | Sold Out | 0 | $0.00 |
| Q1 2023 | -48,047 | Reduce 75.97% | 15,198 | $0.34 |
| Q4 2022 | +42,940 | Add 211.48% | 63,245 | $0.37 |
| Q3 2022 | +33 | Add 0.16% | 20,305 | $323.37 |
| Q2 2022 | -185 | Reduce 0.90% | 20,272 | $324.24 |
| Q1 2022 | +9,045 | Add 79.26% | 20,457 | $286.36 |
| Q4 2021 | +1,530 | Add 15.48% | 11,412 | $276.20 |
| Q3 2021 | +1,002 | Add 11.28% | 9,882 | $231.03 |
| Q2 2021 | -48,843 | Reduce 84.62% | 8,880 | $229.50 |
| Q1 2021 | +57,723 | New Buy | 57,723 | $186.82 |
| Q4 2020 | -11,644 | Sold Out | 0 | $0.00 |
| Q3 2020 | +11,644 | New Buy | 11,644 | $148.06 |
| Q3 2019 | -75,739 | Sold Out | 0 | $0.00 |
| Q2 2019 | +75,739 | New Buy | 75,739 | $110.79 |
| Q1 2019 | -59,043 | Sold Out | 0 | $0.00 |
| Q4 2018 | -13,886 | Reduce 19.04% | 59,043 | $115.71 |
| Q3 2018 | +21,772 | Add 42.56% | 72,929 | $107.31 |
| Q2 2018 | +3,615 | Add 7.60% | 51,157 | $85.33 |
| Q1 2018 | +47,542 | New Buy | 47,542 | $77.36 |
| Q3 2017 | -2,968 | Sold Out | 0 | $0.00 |
| Q2 2017 | -1,032 | Reduce 25.80% | 2,968 | $82.21 |
| Q1 2017 | -14,158 | Reduce 77.97% | 4,000 | $84.00 |
| Q4 2016 | +10,058 | Add 124.17% | 18,158 | $73.58 |
| Q3 2016 | -3,244 | Reduce 28.60% | 8,100 | $80.25 |
| Q2 2016 | -3,563 | Reduce 23.90% | 11,344 | $78.72 |
| Q1 2016 | -300,574 | Reduce 95.27% | 14,907 | $71.98 |
| Q4 2015 | +290,773 | Add 1176.84% | 315,481 | $84.26 |
| Q3 2015 | -233,692 | Reduce 90.44% | 24,708 | $83.70 |
| Q2 2015 | -100,500 | Reduce 28.00% | 258,400 | $83.49 |
| Q1 2015 | +148,100 | Add 70.26% | 358,900 | $72.65 |
| Q4 2014 | +151,800 | Add 257.29% | 210,800 | $68.99 |
| Q3 2014 | -301,300 | Reduce 83.62% | 59,000 | $64.85 |
| Q2 2014 | +355,600 | Add 7565.96% | 360,300 | $62.17 |
| Q1 2014 | -5,700 | Reduce 54.81% | 4,700 | $58.94 |
| Q4 2013 | +3,800 | Add 57.58% | 10,400 | $50.96 |
| Q3 2013 | -4,100 | Reduce 38.32% | 6,600 | $50.30 |
| Q2 2013 | +10,701 | Add 0.00% | 10,700 | $49.16 |
Paul Tudor Jones's Eli Lilly and Company Investment FAQs
Paul Tudor Jones first purchased Eli Lilly and Company (LLY) in Q2 2013, acquiring 10,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Eli Lilly and Company (LLY) for 46 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Eli Lilly and Company (LLY) was in Q2 2014, adding 360,300 shares worth $22.4 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 46,758 shares of Eli Lilly and Company (LLY), valued at approximately $50.25 M.
As of the Q4 2025 filing, Eli Lilly and Company (LLY) represents approximately 0.09% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Eli Lilly and Company (LLY) was 360,300 shares, as reported at the end of Q2 2014.